Page 16 - P4403.59-V63_Numark Pharmacy Magazine May 25
P. 16

2 mg/5 ml
                                                                                                       (400 mcg/ml)

                                                                                                             strength
            The first non-branded 2 mg/5 ml


            glycopyrronium bromide oral solution




            An opportunity for adolescents to continue their treatment into adulthood



            For the symptomatic treatment of severe sialorrhoea (chronic
            pathological drooling) due to chronic neurological disorders of
            childhood-onset in patients aged 3 years and older.
                                                                  1


              Colonis Glycopyrronium Bromide 2 mg/5 ml Oral Solution
              gives patients the opportunity to continue their stable dose
              into adulthood. 1


            •  The 2 mg/5 ml solution is available in 60 ml and 250 ml bottles.
            •  Sugar-free, strawberry flavour – strawberry is the most popular

              flavour with children. 2
            •  A formulation suited for children with swallowing issues. 3

            •  Licensed for use with nasogastric and/or PEG tubes. 1

                                                                                PIP Codes: 128-0841 (60 ml), 128-0833 (250 ml)


                        Colonis Glycopyrronium Bromide Oral Solution 2 mg/5 ml is now
                                          available to order via Phoenix



            PRESCRIBING INFORMATION                                 inhaled anaesthetics. May delay absorption of other medication. Concurrent use with slow-
            Please consult the Summary of Product Characteristics (SmPC) before prescribing.   dissolving tablets of digoxin, atenolol or metformin may result in increased serum levels of these
                                                                    medicines. Use with parasympathomimetics may antagonise the effect.
            Product name: Glycopyrronium Bromide 2 mg/5 ml Oral Solution  Adverse effects:
            Composition: Each 5 ml contains 2 mg of glycopyrronium bromide   Serious: Allergic reaction, seizure (worsening), transient bradycardia, angle-closure glaucoma,
            Indications: Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) due to   urinary retention (common), pneumonia (common), pyrexia (common), behavioural
            chronic neurological disorders of childhood-onset in patients aged 3 years and older.  changes (very common)
            Dosage and administration: Dosing is based on the weight of the child. Using the graduated   Very common: Dry mouth, constipation, diarrhoea, vomiting, flushing, nasal congestion, reduced
            syringe provided, initiate dosing at 0.02 mg/kg three times daily and titrate in increments of   bronchial secretions. Consult the SmPC for further details and for other adverse reactions.
            0.02 mg/kg every 5-7 days. Adjust dose to achieve optimal symptomatic control with minimal   NHS price: 60 ml: £76.80, 250 ml: £320
            adverse effects. The maximum recommended dosage is 0.1 mg/kg three times daily not
            exceeding 1.5-3 mg per dose based on weight. Refer to dosing table (Table 1) in Summary of   Legal category: Prescription Only Medicine
            Product Characteristics. Dose should be given one hour before or two hours after meals. For oral   Marketing Authorisation Holder: Colonis Pharma Limited, 25 Bedford Square, Bloomsbury,
            use and use via nasogastric & PEG feeding tubes.        London, WC1B 3HH, United Kingdom
            Contraindications: Hypersensitivity to glycopyrronium bromide or excipients; angle-closure   MA number: PL 41344/0071
            glaucoma; myasthenia gravis; pyloric stenosis; paralytic ileus; prostatic enlargement; urinary   Job number: GB-CPL-066-001
            retention; severe renal impairment (eGFR < 30 ml/min/1.73 m , including those with end-stage
                                             2
            renal disease requiring dialysis); intestinal obstruction; pregnancy & breastfeeding; potassium   Date of preparation: December 2024
            chloride solid oral dose products; other anticholinergic drugs. Contraindicated during pregnancy
            and whilst breastfeeding.                                Adverse events should be reported. Reporting forms and information can be found
            Warnings and precautions: Not recommended in children under 3 years and should not be used   at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or
            in children with mild to moderate sialorrhoea or in patients over 65 years. Use with caution in   Apple App Store. Adverse events should also be reported to Colonis Pharma Limited via
            children with compromised blood brain barrier. Reduced dose should be considered for patients   Clinigen E-mail: drugsafety@clinigengroup.com
            with renal failure. Use with caution in gastro-oesophageal reflux disease, ulcerative colitis,   Fax number: +44 (0) 1932 824284
            pre-existing constipation, acute myocardial infarction, hypertension, conditions characterised
            by tachycardia (including hyperthyroidism, cardiac insufficiency, cardiac surgery), coronary
            artery disease, cardiac arrhythmias, patients receiving inhalation anaesthesia. Diarrhoea may   Abbreviation
            be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy   PEG, percutaneous endoscopic gastronomy.
            or colostomy, and treatment with this drug would be inappropriate and possibly harmful. As
            glycopyrronium bromide inhibits sweating, patients with increased temperature should be   References
            observed closely. In high environmental temperature, heat prostration can occur. Avoid repeated   1.  Colonis Pharma Ltd. Glycopyrronium Bromide 2 mg/5 ml Oral Solution Summary of Product
            or large doses in patients with uraemia. Patients with fructose intolerance should not take this   Characteristics. Available from: https://www.medicines.org.uk/emc/.
            medicine due to presence of sorbitol. The product contains sodium propyl parahydroxybenzoate   2.  Generation R. What flavour would children choose for their medicines? Available from: https://
            (E217) and sodium methyl parahydroxybenzoate (E219) which may cause allergic reactions   generationr.org.uk/what-flavour-would-children-choose-for-their-medicines/
                                                                      [Accessed January 2025].
            (possibly delayed). Treatment should be evaluated in the event of constipation, overheating,   3.  Batchelor HK and Mariott JF. Formulations for children; problems and solutions. Br J Pharmacol.
            urinary retention, pneumonia, allergic reaction, pyrexia, very hot weather, changes in behaviour.   2015;79(3):405–418.
            Safety data beyond 24 weeks are not available. Treatment should be kept as short as possible.
            May produce drowsiness or blurred vision, thus patients should not operate machinery.  © Colonis Pharma Limited 2025
            Drug interactions: Combinations with drugs with antimuscarinic effects (e.g. amantadine,   Registered in England & Wales No. 05486832. For more information please view our Privacy
            tricyclic antidepressants, antihistamines, clozapine; disopyramide; MAOIs, nefopam; memantine,   Policy. VAT Registration No. 862418028. Registered office: Colonis Pharma Ltd, 25 Bedford Square,
            phenothiazines) may add to adverse effects and can also lead to confusion in the elderly. Use   Bloomsbury, London, WC1B 3HH.
            with corticosteroids may result in increased intraocular pressure. There are specific interactions
            with domperidone, metoclopramide, levodopa, haloperidol; nitrates; topiramate, zonisamide;   January 2025 | GB-CPL-066-002
                                                                                                                 14/04/2025   12:45:38
         P4403.59-V63_Numark Pharmacy Magazine May 25 -.indd   16                                                14/04/2025   12:45:38
         P4403.59-V63_Numark Pharmacy Magazine May 25 -.indd   16
   11   12   13   14   15   16   17   18   19   20   21